CAS 752187-80-7

CP 544326

CAS : 752187-80-7

Formule : C₂₄H₂₂N₄O₅S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 478.5203

Ref: IN-DA00G3SQ

Taprenepag

CAS : 752187-80-7

Taprenepag

Degré de pureté : ≥98%

Masse moléculaire : 478.52g/mol

Ref: 54-BUP13038

2-(3-((N-(4-(1H-Pyrazol-1-Yl)Benzyl)Pyridine-3-Sulfonamido)Methyl)Phenoxy)Acetic Acid

CAS : 752187-80-7

2-(3-((N-(4-(1H-Pyrazol-1-Yl)Benzyl)Pyridine-3-Sulfonamido)Methyl)Phenoxy)Acetic Acid

Degré de pureté : 98%

Masse moléculaire : 478.52g/mol

Ref: 54-OR1022927

Taprenepag

CAS : 752187-80-7

Taprenepag (CP-544326) (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM).

Formule : C₂₄H₂₂N₄O₅S

Degré de pureté : 98.89% - 99.15%

Couleur et forme : Solid

Masse moléculaire : 478.52

Ref: TM-T3174

Taprenepag

CAS : 752187-80-7

Taprenepag is a prodrug that is hydrolyzed to its active form, the camphor derivative, in the body. Camphor derivatives are a class of compounds that are used as drugs and have been shown to have anticancer activity. Taprenepag has been shown to inhibit the growth of cervical cancer cells by binding to response element-binding protein (RBP) and inhibiting cell proliferation. It also inhibits angiogenic factors such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO), which are involved in tumor growth. The compound also inhibits PI3K/Akt/mTOR signaling pathway, which may contribute to its anti-cancer activity. Taprenepag has been shown to be effective in models of bowel disease, such as inflammatory bowel disease and ulcerative colitis. In addition, this drug has been studied for use in skin cancer treatment with benzalkonium chloride.

Formule : C₂₄H₂₂N₄O₅S

Degré de pureté : Min. 95%

Masse moléculaire : 478.52 g/mol

Ref: 3D-CFB18780